Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2002
01/24/2002US20020010187 5-((4-(3-methyl-4-oxo-3,4-dihydro-2 -quinazolinyl)methoxy)phenylmethyl)thiazolidine-2 ,4-dione or a pharmaceutically acceptable salt thereof
01/24/2002US20020010186 Dihydropyrimidines and uses thereof
01/24/2002US20020010185 Anticarcinogenic agents
01/24/2002US20020010183 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
01/24/2002US20020010181 Angiogenesis inhibitors as antitumor agents
01/24/2002US20020010180 Treatment of rheumatoid arthritis, Crohn's disease, acute and chronic immune diseases associated with transplantation
01/24/2002US20020010178 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect
01/24/2002US20020010177 For treating eosinophil-dependent inflammatory diseases, asthma
01/24/2002US20020010175 Diazepinoindoles for the treatment of chronic obstructive pulmonary disease
01/24/2002US20020010174 1,4-diazepine-2-one derivatives as neurokinin antagonist
01/24/2002US20020010173 Reacting an amide derivative with a piperidine containing guanidine group to produce the product
01/24/2002US20020010172 Lactams as inhibitors of A-beta protein production
01/24/2002US20020010171 New compounds, their preparation and use
01/24/2002US20020010170 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli
01/24/2002US20020010168 Boswellic acid, salt or derivatives for preventing and/or combatting diseases caused by increased leucocytic elastase or plasmin activity in human or veterinary medincine, usedfor pulmonary emphysema, acute respiratory distress etc.
01/24/2002US20020010167 An oral contraceptive starter kit comprising at least two cycle packs of oral contraceptives containing an estrogen and a progestin, and having penultimate cycle with greater steroid dosage than last cycle pack dosage
01/24/2002US20020010166 Crystalline progestagens
01/24/2002US20020010165 Treating the hypercalcemia associated with malignant or neoplastic cells with an effective amount of a hypocalcemic vitamin D compound having a hydrocarbon moiet at the 24 position
01/24/2002US20020010163 Pregnacalciferol derivatives and corresponding 5,6-trans isomers exhibit anti-progesterone activity and may be useful as antineoplastic, antifertility, antiproliferative, immunosuppressive or antiinflammatory agents
01/24/2002US20020010162 Administering, to a patient suffering from psoriasis, a therapeutically effective amount of tetracyclines, orhydroxymate, carboxylate or phosphonic acid derivatives, as an inhibitor of a matrix metalloproteinase enzyme
01/24/2002US20020010161 Orally administering to the mammal to prevent bone resorption a pharmaceutically effective amount of a bisphosphonate as a unit dosage according to a continuous schedule having selective dosing intervals
01/24/2002US20020010160 Therapeutic agents
01/24/2002US20020010158 Derivatives of 5-pyridylalkylphosphonates and 5-pyridylalkylmalonates useful drugs for treatment of cardiovascular related diseases and diabetes mellitus related diseases
01/24/2002US20020010153 Oral delivery of macromolecules
01/24/2002US20020010152 Composition consisting of heparin fractions having reproducible characteristics with average molecular weight equal to 5200d
01/24/2002US20020010151 Immuno-active agent, method of its use, and method of immunity activation
01/24/2002US20020010150 Homostatic compositions of polyacids and polyalkylene oxides and methods for their use
01/24/2002US20020010149 Therapeutic agent for a cancer and method of screening the same, and health-care auxiliary food
01/24/2002US20020010147 High purity of the diastereoisomer; acidifying pH, making an aqueous lysate from the yeast, microfiltration of lysate, absorption on a weak acid resin, elution with inorganic acid, decoloration, reverse osmosis, adding acid to form salt
01/24/2002US20020010146 Nitrosated and nitrosylated taxanes, compositions and methods of use
01/24/2002US20020010142 Parasiticidal formulation and a method of making this formulation
01/24/2002US20020010141 Isoflavones for treatment of obesity
01/24/2002US20020010140 Use of pentosan polysulfate to treat certain conditions of the prostate
01/24/2002US20020010133 Method for preventing gastritis using amylin or amylin agonists
01/24/2002US20020010128 Treating atopic dermatitis and/or skin photodamage, by administering a HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase) inhibitor
01/24/2002US20020010127 Dosage form; antagonist to attenuate a side effect of said opioid agonist; analgesia for at least about eight hours when administered to human patients
01/24/2002US20020010126 Administering an agent which antagonizes the effects of a colony stimulating factor on these monocyte/macrophage cells to lower levels or reduce their activity; treating inflammation
01/24/2002US20020010125 Chemokinesis interferes with immune and inflammatory responses by increasing cell movements and altering cell migration patterns; interfere with spread of malignant cells through the body, and reduce inflammatory responses
01/24/2002US20020010098 Insecticides, nematodicides
01/24/2002US20020009802 Removing preferential microorganism from sample; obtain sample, incubate with prophylactic agent, monitor sample for presence of microorganism
01/24/2002US20020009800 Genetically engineeered sequences for use in gene therapy of central nervous system
01/24/2002US20020009783 Aqueous solutions comprising a polysaccharide oncotic agent, a physiologically compatible buffer, a simple hexose sugar, dissolved chloride salt of sodium, calcium and magnesium and an organic acid or salt or ester, substitute for blood
01/24/2002US20020009764 Antitumor agents for use in treatment of cancer
01/24/2002US20020009714 Use of azetidinone compounds
01/24/2002US20020009510 Plant extracts for the treatment of increased bone resorption
01/24/2002US20020009509 Soya extract containing lipids, process for its production, and pharmaceutical and cosmetic composition
01/24/2002US20020009507 Antiinflammatory agents; mimic or enhance tears
01/24/2002US20020009506 Plant extracts, herbs, natural nutritional supplements, minerals and vitamins
01/24/2002US20020009505 Compositions and methods for treating eye discomfort
01/24/2002US20020009504 Herbs, natural nutritional supplements, minerals, vitamins and plant extracts; antiinflammatory agents
01/24/2002US20020009502 Water, sodium chloride, potassium chloride, sodium citrate, potassium citrate, carbohydrates and structuring agents; masks unpleasant tastes
01/24/2002US20020009496 Spraying a suspension of microionized fenofibrate and polyvinylpyrrolidone onto an inert hydrosoluble carrier; immediate-release; improved dissolution
01/24/2002US20020009494 Spray drying
01/24/2002US20020009491 Compositions and methods for enhancing drug delivery across biological membranes and tissues
01/24/2002US20020009483 Topical administration of oxazolidinones for transdermal delivery
01/24/2002US20020009482 Activation
01/24/2002US20020009481 Substance with antiobese and cumulative visceral fat-reducing actions and use thereof
01/24/2002US20020009478 Aqueous liquid containing colloidal particles
01/24/2002US20020009467 Antigenic substance inductor, vaccine precursor, vaccine, antibody, neutralizing antibody, antitoxin, idiotype antibody and/or anti-idiotype antibody which is induced by its idiotype antibody
01/24/2002US20020009461 Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
01/24/2002US20020009455 Prostate glands; diagnosis, therapy
01/24/2002US20020009444 Brain disorders using monoclonal antibodies
01/24/2002US20020009433 Method of increasing the bioavailability and tissue penetration of azithromycin
01/24/2002US20020009428 Combination therapy for cancer
01/24/2002US20020009423 Using hydroxyacid or tannic acid
01/24/2002US20020009421 Oral administering cyclooxygenase inhibitor
01/24/2002US20020009418 Dry powder formulations of antihistamine for nasal administration
01/24/2002DE19963234A1 New N,N-disubstituted piperazine and diazacycloheptane derivatives useful in treatment of hyperlipidemia, atherosclerosis, diabetes mellitus, adiposity and pancreatitis
01/24/2002DE10053375C1 Transdermal therapeutic system with light-sensitive agent in polymer matrix and backing, useful for therapy with e.g. nicotine, nifedipine, lacidipine, gestagen, vitamin B 12 or antibiotic, contains colorless ultraviolet absorber
01/24/2002DE10034233A1 Tocotrienolchinon-Cyclisierungsprodukte Tocotrienolquinone cyclization products
01/24/2002DE10034138A1 Wirkstoffkombinationen aus 3-Iodo-2-propinyl-butylcarbomat und Phenoxyethanol und Zubereitungen, solche Wirkstoffkombinationen enthaltend Active compound combinations of 3-iodo-2-propynyl-butylcarbomat and phenoxyethanol and preparations such active ingredient combinations
01/24/2002DE10034137A1 Wirkstoffkombinationen aus 3-Iodo-2-propinyl-butylcarbamat und einem oder mehreren 4-Hydroxybenzoesäureestern und Zubereitungen, solche Wirkstoffkombinationen enthaltend Active compound combinations of 3-iodo-2-propynyl butyl carbamate and one or more 4-hydroxybenzoic acid and preparations such active ingredient combinations
01/24/2002DE10034136A1 Wirkstoffkombinationen aus 3-Iodo-2-propinyl-butylcarbamat, einem oder mehreren 4-Hydroxybenzoesäureester und Phenoxyethanol und Zubereitungen, solche Wirkstoffkomibnationen enthaltend Active compound combinations of 3-iodo-2-propynyl butyl carbamate, one or more 4-hydroxybenzoic acid esters and phenoxyethanol and preparations containing such Wirkstoffkomibnationen
01/24/2002DE10034132A1 Heterocyclische Fluoralkenylthioether (lll) Heterocyclic fluoroalkenyl thioethers (III)
01/24/2002DE10034131A1 Heterocyclische Fluoralkenylthioether (II) Heterocyclic fluoroalkenyl thioethers (II)
01/24/2002DE10034130A1 Heterocyclische Fluoralkenylthioether (lV) Heterocyclic fluoroalkenyl thioethers (IV)
01/24/2002DE10034102A1 Cosmetic or dermatological gels including iminodisuccinic acid to inhibit skin irritation, especially stinging
01/24/2002DE10034101A1 Cosmetic or dermatological emulsions including iminodisuccinic acid to inhibit skin irritation, especially stinging
01/24/2002DE10033459A1 New aminomethyl-substituted bicyclic compounds, useful for treating urinary incontinence, pruritis, tinnitus, diarrhea or especially pain
01/24/2002DE10032964A1 Verwendung von Kreatin und/oder Kreatingderivaten in kosmetischen oder dermatologischen Zubereitungen Use of creatine and / or creators Ting derivatives in cosmetic or dermatological preparations
01/24/2002DE10032224A1 Rapidly acting analgesic for treating acute, severe pain, comprises intravenously administered aqueous solution of o-carbamoyl-phenoxyacetic acid
01/24/2002CA2429008A1 Lipid-rich plaque regressing agents
01/24/2002CA2419626A1 Imidazo¬1,2-a|pyrazines for the treatment of neurological disorders
01/24/2002CA2418288A1 Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors
01/24/2002CA2418214A1 Antimicrobial agent
01/24/2002CA2418162A1 Use of il-8 receptor antagonists in the treatment of virus infections
01/24/2002CA2418146A1 Use of matrix metalloprotease inhibitors for the treatment of cancer
01/24/2002CA2417736A1 Sildenafil citrate solid dispersions having high water solubility
01/24/2002CA2416986A1 Crf2 ligands in combination therapy
01/24/2002CA2416667A1 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists
01/24/2002CA2416248A1 5-substituted 2-aryl-4-pyrimidinones
01/24/2002CA2416245A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists
01/24/2002CA2416187A1 Use of 2.alpha.-methyl-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase bone strength
01/24/2002CA2416015A1 Matrix metalloproteinase inhibitors
01/24/2002CA2415965A1 Oxazolidinone derivatives as antimicrobials
01/24/2002CA2415935A1 Novel 6-heteroarylphenanthridines
01/24/2002CA2415932A1 Cyclic oxyguanidine pyrazinones as protease inhibitors
01/24/2002CA2415922A1 Pharmaceutical compositions containing dds compound
01/24/2002CA2415906A1 Compositions containing diacyltartaric salts of (e)-metanicotine
01/24/2002CA2415901A1 Pharmaceutical compositions and methods for use